Ono's antisense therapy is to begin its first pivotal trial.
ApexOnco Front Page
Recent articles
Precemtabart tocentecan could soon become the industry's most advanced anti-CEACAM5 ADC.
New data with pasritamig plus docetaxel support a recent pivotal start.
Decisions and readouts loom for the SERDs Astra’s camizestrant and Roche’s giredestrant.
The month saw the first commissioner's priority voucher approval in oncology.
The first fruit of a long-standing deal with Roche enters phase 1 in March.
An FDA verdict is due in the third quarter, as Protagonist looks likely to opt out.
But biomarker enrichment and toxicity remain key for FX-909.
